Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?
Reposted from
Saad Z. Usmani, MD
Up next, the #ASH24 #MyelomaSky **Clinical Abstracts - RRMM @ash-hematology.bsky.social
1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
ash.confex.com/ash/2024/web...
1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
ash.confex.com/ash/2024/web...
Comments